Aurobindo Pharma FY26 Results

Aurobindo Pharma reported consolidated revenue of ₹33,653 crore for the fiscal year ended March 2026, marking a 6.1% increase from ₹31,724 crore in FY25. Profit After Tax (PAT) saw a marginal rise of 0.6% to ₹3,503 crore, with Earnings Per Share (EPS) at ₹60.34.

Reader Takeaway: European growth driver; US pricing pressure remains a concern.

What just happened

Aurobindo Pharma announced its financial results for FY26, showcasing a 6.1% revenue growth to ₹33,653 crore. The company's EBITDA stood at ₹6,856 crore, maintaining a healthy EBITDA margin of approximately 20.4%. PAT grew by 0.6% to ₹3,503 crore.

Why this matters

The results indicate the company's ability to expand its top line despite challenges in key markets like the US. The strong performance in Europe, crossing €1 billion in revenue, is a significant positive. However, persistent pricing pressures in the US and global geopolitical risks are points to monitor.

The backstory

In previous years, Aurobindo Pharma has focused on expanding its global footprint, investing heavily in research and development, and scaling up manufacturing capabilities. Recent strategic moves include acquisitions aimed at strengthening its market position and product portfolio.

What changes now

The company's FY26 performance reinforces its strategy of diversification and investment in complex product segments. The successful commercialisation of the Pen-G facility in Kakinada is a step towards backward integration. Investors will be looking at how acquisitions like Lannett and Khandelwal Laboratories integrate and contribute to future growth.

Risks to watch

Key concerns include ongoing pricing pressures in the US pharmaceutical market, potential supply chain disruptions due to geopolitical instability, and reliance on single manufacturing sites for certain products. The company's ability to navigate these risks while expanding its biosimilar offerings will be crucial.

Peer comparison

While the filing does not provide direct peer comparison, the company's revenue growth of 6.1% and steady EBITDA margin suggest resilience in a competitive global pharmaceutical landscape. Competitors often face similar pricing challenges in regulated markets.

Context metrics (time-bound)

• Consolidated Revenue (FY26): ₹33,653 crore (up 6.1% from FY25)
• EBITDA (FY26): ₹6,856 crore (up 3.8% from FY25)
• PAT (FY26): ₹3,503 crore (up 0.6% from FY25)
• R&D Investment (FY26): ₹1,590 crore (~5% of revenue)
• CAPEX Spent (FY26): ₹3,058 crore
• European Business Revenue (FY26): Over €1 billion (~₹10,315 crore)
• Pen-G Facility Production (FY26): Over 10,000 MT

What to track next

Investors should closely monitor the integration and performance of recently acquired businesses, the progress of biosimilar filings and approvals in regulated markets, and the company's response to pricing and cost challenges in the US and Europe. The 39th Annual General Meeting (AGM) is scheduled for August 27, 2026.